<SUBMISSION>
<ACCESSION-NUMBER>0001023024-07-000024
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20071113
<ITEMS>2.02
<ITEMS>9.01
<FILING-DATE>20071113
<DATE-OF-FILING-DATE-CHANGE>20071113
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>BIOSANTE PHARMACEUTICALS INC
<CIK>0001023024
<ASSIGNED-SIC>2836
<IRS-NUMBER>582301143
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-31812
<FILM-NUMBER>071238826
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>111 BARCLAY BLVD STE 280
<CITY>LINCOLNSHIRE
<STATE>IL
<ZIP>60069
<PHONE>8474780500
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>111 BARCLAY BLVD STE 280
<CITY>LINCOLNSHIRE
<STATE>IL
<ZIP>60069
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>BEN ABRAHAM TECHNOLOGIES INC
<DATE-CHANGED>19991027
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>biosante8kforq32007.htm
<DESCRIPTION>2007 Q3 8K
<TEXT>
<html>

  <head>
    <title>biosante8kforq32007.htm</title>
<!-- Licensed to: BioSante Pharmaceuticals-->
<!-- Document Created using EDGARizer 4.0.1.0 -->
<!-- Copyright 2007 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font id="TAB1" style="MARGIN-LEFT: 468pt;"></font><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Washington,
      D.C.&#160;&#160;20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">__________________</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman;"><strong>FORM
      8-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Current
      Report</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Pursuant
      to Section 13 or 15(d) of the Securities Exchange Act of
      1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">__________________</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Date
      of
      Report (Date of earliest event reported):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>November
      13, 2007</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman;"><strong>BIOSANTE
      PHARMACEUTICALS, INC.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">(Exact
      name of registrant as specified in its charter)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;"><strong>Delaware</strong></font></div>
            </td>
            <td valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;"><strong>001-31812</strong></font></div>
            </td>
            <td valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;"><strong>58-2301143</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;">(State
                or Other Jurisdiction of Incorporation)</font></div>
            </td>
            <td valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;">(Commission
                File Number)</font></div>
            </td>
            <td valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;">(I.R.S.
                Employer Identification Number)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="top" width="40%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;"><strong>111
                Barclay Boulevard</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;"><strong>Lincolnshire,
                Illinois</strong></font></div>
            </td>
            <td valign="top" width="40%">
              <div>&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;"><strong>60069</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="40%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;">(Address
                of Principal Executive Offices)</font></div>
            </td>
            <td valign="top" width="40%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;">(Zip
                Code)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>(847)
      478-0500</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">(Registrant&#8217;s
      Telephone Number, Including Area Code)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>N/A</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">(Former
      Name or Former Address, If Changed Since Last Report)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Check
      the
      appropriate box below if the Form 8-K filing is intended to simultaneously
      satisfy the filing obligation of the registrant under any of the following
      provisions:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top">
            <td align="right" style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Wingdings 2, serif">&#163;&#160;&#160;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Written
                communications pursuant to Rule 425 under the Securities Act (17
                CFR
                230.425)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top">
            <td align="right" style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Wingdings 2, serif">&#163;&#160;&#160;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Soliciting
                material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
                240.14a-12)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top">
            <td align="right" style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Wingdings 2, serif">&#163;&#160;&#160;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Pre-commencement
                communications pursuant to Rule 14d-2(b) under the Exchange Act (17
                CFR
                240.14d-2(b))</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top">
            <td align="right" style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Wingdings 2, serif">&#163;&#160;&#160;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Pre-commencement
                communications pursuant to Rule 13e-4(c) under the Exchange Act (17
                CFR
                240.13e-4(c))</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font id="TAB1" style="MARGIN-LEFT: 468pt;"></font><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div><br></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Section
      2 &#8211; Financial Information</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Item
      2.02. Results of Operations and Financial Condition</strong>.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">On
      November 13, 2007, BioSante Pharmaceuticals, Inc. publicly announced its
      financial results for the third quarter ended September 30, 2007.&#160;&#160;For
      further information, please refer to the press release attached hereto as
      Exhibit 99.1, which is incorporated by reference herein.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">The
      information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be
      deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act
      of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability
      of that section, and shall not be incorporated by reference into any filings
      made by BioSante Pharmaceuticals, Inc. under the Securities Act of 1933, as
      amended, or the Exchange Act, except as may be expressly set forth by specific
      reference in such filing.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Section
      9 &#8211; Financial Statements and Exhibits</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Item
      9.01. Financial Statements and Exhibits.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<em>Exhibits</em>.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;">Exhibit
                  No.</font></div>
              </div>
            </td>
            <td valign="top" width="59%" style="BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;">Description</font></div>
              </div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="10%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;">99.1</font></div>
            </td>
            <td align="justify" valign="top" width="59%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;">Press
                Release issued November 13, 2007</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>SIGNATURE</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Pursuant
      to the requirements of the Securities Exchange Act of 1934, the registrant
      has
      duly caused this report to be signed on its behalf by the undersigned hereunto
      duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 216pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>BIOSANTE
      PHARMACEUTICALS, INC.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 216pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">By:<u>&#160;&#160;/s/
      Phillip B.
      Donenberg</u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 234pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Phillip
      B. Donenberg</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 234pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><em>Chief
      Financial Officer, Treasurer and Secretary</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Dated:&#160;&#160;<strong>&#160;</strong>November
      13, 2007</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>BIOSANTE
      PHARMACEUTICALS, INC.</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>FORM
      8-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong><u>Exhibit
      Index</u></strong></font></div>
    <div><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;"><strong>Exhibit
                  No.</strong></font></div>
              </div>
            </td>
            <td valign="bottom" width="41%" style="BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;"><strong>Description</strong></font></div>
              </div>
            </td>
            <td valign="bottom" width="25%" style="BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;"><strong>Method
                  of Filing</strong></font></div>
              </div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="11%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;">99.1</font></div>
            </td>
            <td align="justify" valign="top" width="41%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;">Press
                Release issued November 13, 2007</font></div>
            </td>
            <td valign="top" width="25%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;">Furnished
                herewith</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
  </body>
</html>


















</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pressrelease.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>

  <head>
    <title>pressrelease.htm</title>
<!-- Licensed to: BioSante Pharmaceuticals-->
<!-- Document Created using EDGARizer 4.0.1.0 -->
<!-- Copyright 2007 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff"><img src="biosantelogo6.jpg" alt=""><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>BioSante
        Pharmaceuticals, Inc. </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">111
        Barclay Boulevard</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Lincolnshire,
        Illinois 60069</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">www.biosantepharma.com</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><br></font>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>FOR
              IMMEDIATE
              RELEASE&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</strong></font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>NASDAQ:
              BPAX</strong></font></div>
            <div><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;"><strong>BioSante
              Pharmaceuticals Reports</strong></font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;"><strong>Third
              Quarter 2007 Financial Results</strong></font></div>
            <div><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>LINCOLNSHIRE,
              Illinois - (November 13, 2007) ---</strong> BioSante Pharmaceuticals, Inc.
              (NASDAQ: BPAX) today reported its September 30, 2007 cash balance and
              its
              financial results for the third quarter and nine months ended September
              30,
              2007.</font></div>
            <div><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">The
              Company&#8217;s cash, cash equivalents and short-term investments as of September
              30,
              2007 were approximately $29.4 million, as compared to approximately
              $11.5
              million on December 31, 2006.&#160;The Company&#8217;s cash burn rate in the last
              quarter of 2007 is expected to be approximately $750,000 per month
              as its
              LibiGel<font style="DISPLAY: inline; FONT-SIZE: 10pt;"><sup>&#174;</sup></font>
              (transdermal testosterone gel) Phase III clinical development progresses
              for the
              treatment of female sexual dysfunction.</font></div>
            <div><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">BioSante
              incurred a net loss of approximately $1.7 million (or $0.06 per share)
              for the
              quarter ended September 30, 2007 and $5.9 million (or $0.24 per share)
              for the
              nine months ended&#160;September 30, 2007, compared to a net loss of $0.7
              million (or $0.03 per share) and $6.2 million (or $0.30 per share)
              for the same
              periods in 2006.</font></div>
            <div><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>About
              BioSante Pharmaceuticals, Inc</strong>.</font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">BioSante
              is developing a pipeline of hormone therapy products to treat both
              men and
              women.&#160;&#160;These hormone therapy products are gel formulations for
              transdermal administration that deliver bioidentical estradiol and
              testosterone.&#160;&#160;BioSante's lead products include Elestrin&#8482; (estradiol
              gel) developed through U.S. Food and Drug Administration (FDA) approval
              by
              BioSante indicated for the treatment of moderate-to-severe vasomotor
              symptoms
              associated with menopause, marketed in the U.S.&#160;by Bradley Pharmaceuticals,
              Inc., BioSante's licensee, and LibiGel<font style="DISPLAY: inline; FONT-SIZE: 10pt;"><sup>&#174;</sup></font>
              (transdermal
              testosterone gel) in Phase III clinical development by BioSante for
              the
              treatment of female sexual dysfunction (FSD).&#160;&#160;Also in development are
              Bio-T-Gel&#8482;, a testosterone gel for male hypogonadism, and an oral contraceptive
              in Phase II clinical development using BioSante patented
              technology.&#160;&#160;&#160;The current market in the U.S. for estrogen and
              testosterone products is approximately $2.5 billion and for oral contraceptives
              approximately $3.0 billion. The company also is developing its calcium
              phosphate
              nanotechnology (CaP) for novel vaccines, drug delivery, and aesthetic
              medicine.&#160;&#160;Additional information is available online at
              www.biosantepharma.com.</font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><em>This
              news release contains forward-looking statements within the meaning
              of the
              Private Securities Litigation Reform Act of 1995.&#160;&#160;The statements
              regarding BioSante contained in this news release that are not historical
              in
              nature, particularly those that utilize terminology such as &#8220;may,&#8221; &#8220;will,&#8221;
&#8220;should,&#8221; &#8220;would,&#8221; &#8220;likely,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; &#8220;believes,&#8221;
&#8220;plans,&#8221; &#8220;hopes,&#8221; or comparable terminology, are forward-looking
              statements.&#160;&#160;The statement regarding BioSante&#8217;s expected cash burn
              rate for fourth quarter 2007 is a forward-looking statement. Forward-looking
              statements are based on current expectations and assumptions, and entail
              various
              risks and uncertainties that could cause actual results to differ materially
              from those expressed in such forward-looking statements.&#160;&#160;Important
              factors known to BioSante that could cause actual results to differ
              materially
              from those expressed in such forward-looking statements include the
              difficulty
              of developing pharmaceutical products, obtaining regulatory and other
              approvals
              and achieving market acceptance, the success of clinical testing, and
              other
              factors identified and discussed from time to time in BioSante's filings
              with
              the Securities and Exchange Commission, including those factors discussed
              in
              BioSante's most recent annual report on Form 10-K and subsequent quarterly
              reports on Form 10-Q, which discussions also are incorporated herein
              by
              reference.&#160;&#160;All forward-looking statements speak only as of the date
              of this news release.&#160;&#160;BioSante undertakes no obligation to update or
              revise any forward-looking statement, whether as a result of new information,
              future events or otherwise.</em></font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            <div><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>For
              more information, please contact:</strong></font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Alan
              Zachary, McKinney/Chicago; (312) 944-6784 ext. 316; <font style="DISPLAY: inline; FONT-SIZE: 10pt;">azachary@mckinneychicago.com</font>;
              www.mckinneychicago.com</font></div><br></div>
        </div>
      </div>
    </div>
  </body>
</html>
















</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>biosantelogo6.jpg
<DESCRIPTION>LOGO
<TEXT>
begin 644 biosantelogo6.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!P17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@#`P#$!`@`9````3@``````
M``!@`````0```&`````!````141'05)I>F5R(%-O9G1W87)E(%-U:71E`'W_
MVP!#``8$!`4$!`8%!04&!@8'"0X)"0@("1(-#0H.%1(6%A42%!07&B$<%Q@?
M&104'2<='R(C)24E%API+"@D*R$D)23_VP!#`08&!@D("1$)"1$D&!08)"0D
M)"0D)"0D)"0D)"0D)"0D)"0D)"0D)"0D)"0D)"0D)"0D)"0D)"0D)"0D)"0D
M)"3_P``1"`"/`5$#`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"
M`P0%!@<("0H+_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A
M!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%
M1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9
MFJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?H
MZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+
M_\0`M1$``@$"!`0#!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1
MH;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::G
MJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W
M^/GZ_]H`#`,!``(1`Q$`/P#QW_A8_C/_`*&C5_\`P*?_`!H/Q(\9#_F9]8_\
M"G_QKFJ&^[7Z$\/2M\*%<]NTGP)\;-;TZUU&SUK4&M[F)9HW.H'H>1D9]*L_
M\*O^/'_07OO_``8G_&OHOX6'/P[\.GJ?[/AY_P"`BM'6/&.@>'Y%BU;6+&PD
M<95;B94+?3-?(SS"I[1QC!:>11\Q_P#"KOCQ_P!!:_\`_!D?\::_PS^/D8.-
M1U.7Z:EC^M?1_P#PM#P5_P!#3HW_`(%I_C5G3O'7AG6)1!IVOZ9<R$XVPW"L
MWY9IO,*RW@O_``$SLCX]\0Q?%_PFC-K-YXC@1>LHN&9%^K`X_6N8_P"%D>,_
M^AGU?_P*?_&OT!NK&VO;9X+B&.6*089'7(-?$_QX^'<'P_\`&#+9*$T^_4SP
MQD\+_>4?ICZUZ&7X^GB'[.I!)E6-7PQX5^,GC#28=6TK6]0FM)B<.;\@\>VZ
ML_QK#\4_A\EN^O:_JD/VHD1[;UFZ?0U[?\`O%^@:7\-+"VO]:L+69&?,<DRJ
MPR>.IKA_VJO$.CZ]!HBZ;J=I>B-W+>1('VC'7@U%"O4GBO9."MZ!8\;_`.%D
M^,O^AGU?_P`"G_QH_P"%C^,_^AHU?_P*?_&N:HKZ'ZM2_E07.E_X6/XS_P"A
MHU?_`,"G_P`:/^%C^,_^AGU?_P`"G_QKFJ*/J]+^5!<Z3_A9'C+_`*&?5_\`
MP*?_`!I?^%D^,?\`H:=7_P#`I_\`&N:^M=?\*/!+>/\`QK8Z1)G[.#YD^./D
M'6HK4Z%*#G**T"YI>'M0^*OBV39HNI>(KPD\ND[[!_P(G%=G#\-/CS(NYM1U
M.//\+ZES^AKZFT;0;#P]I\6GZ=;1VT$2[0JC'X^YJOJ_B_0=!(74M9L+-C_S
MWG52?SKY6IFDI3_=4U;T"Q\R?\*O^/'_`$%K_P#\&1_QI/\`A5_QX_Z"U]_X
M,C_C7T=_PM'P5_T-6C?^!:_XT?\`"T/!7_0U:-_X%I_C2^OU_P#GVON%9'SB
M?AA\=U!+:M?X`R?^)D?\:\TO_'GCC3[V:SN/$FK)+"Y1T%V_!'H<U]JW'Q/\
M%-;RA?%.CDE"`!=+Z?6OA7Q1-'=^)-3EA9)8WN7977D$9Z@UZ>55)8B;C5@O
MN'8O_P#"R/&>/^1GU?\`\"G_`,:/^%C^,_\`H:-7_P#`I_\`&N:HKV_JU+^5
M!<Z7_A8_C/\`Z&C5_P#P*?\`QH_X6/XS_P"AHU?_`,"G_P`:YJBCZM2_E07.
ME_X6/XS_`.AHU?\`\"G_`,:/^%C^,_\`H:-7_P#`I_\`&N:HH^K4OY4%SI?^
M%C^,_P#H:-7_`/`I_P#&C_A8_C/_`*&C5_\`P*?_`!KFJ*/JU+^5!<Z7_A8_
MC/\`Z&C5_P#P*?\`QH_X6/XS_P"AGUC_`,"G_P`:YJBCZM2_E07.F3XD>,BX
M'_"3ZO\`C=/U_.O4+;X:_'*[MX[B'6+]HY%#J?[0(R",CO7A<?\`K%^HK]&_
M#P']@Z=Q_P`N\?\`Z"*\7-JRPS4:<5KY"@?#GB/Q+\0/">KW&D:GXDU6.\@(
M#A;UB*RC\1_&?_0SZO\`^!3_`.-;_P`?N/BKK7;]X/Y5YW7J86C3J48U'%7&
M=+_PL?QG_P!#1J__`(%/_C1_PL?QG_T-&K_^!3_XUS5%;?5J7\J"YTO_``L?
MQG_T-&K_`/@4_P#C1_PL?QG_`-#1J_\`X%/_`(US5%'U>E_*@N=+_P`+'\9_
M]#1J_P#X%/\`XU=T7XB^,)=8L8W\2ZNR-.@93<M@C(]ZXVM#0?\`D.:?_P!?
M$?\`Z$*BMAZ2@[107/O3SY_^?B7_`+ZHJ*BOB2SX`H;[M%#?=K[Y[$'Z!_"S
M_DG?AW_L'P_^@"OGO]K\#_A)]$_Z]G/ZU]!_"O\`Y)UX>_[!\/\`Z"*Q_B)\
M&-!^)=]:WFL3WD3VR%$%NX'!]<BOAL-7C0Q3J3V0SX6V#T%36ES<65Q'/;2/
M%-&P*,AP<^QKZZ_X9,\#?\_>K?\`?Y?\*N:-^S%X%T;4$O,7UX8CN$4\@*`_
M0#FO=K9YAI1T3^X5CT3P?<W-]X4TFYN]QN);2)Y,\%F*`GZ<U\\_M@2QF]\/
MP84SA)&^BY%?1&O^(-,\'Z+)?ZA,MO:6Z]<?D,"OA[XJ^/9_B)XKGU9E9+9%
M,5M&>T?8_4UY>4474Q"J+9$S/3/A?^SKH_CKP;::]<ZI>033LV5C`(X..E<S
M\<?A!8?"Y--:PO;BY^V%U/FCIQ7T'^S>!_PJO3!@???^=>??MA`+#X?./^6C
M_P`JZ,/C*TL=[-RTO:Q1\S!2S!5!))P`*]F^'G[->M^+8(M1U>;^RK*3!12,
MR2#UQV_&H_V;OAW!XM\5OJFHP![+3,-L89#R'[N?YU];:[K-AX8TB?4[UUAM
M;:,L3].PKIS/,YTY^PH;]Q6/(8/V2_!448\V]U:5^[>8H_3%8'B7]DFS:&23
MP_JTZ2C[L-V`RO\`B.E9&L_M;:O)J#G1]'MA:(V%\\DNX]>.!7J?PA^-=E\2
MU>RG@^PZI"-[0[LK(/537GS_`+0HQ]M-Z!H?(/BKPIJO@O5'TS6+-X)U/RY'
M##U4]Q7L'[(]K%+XNU29\%X[;Y<CIDU[/\<?AW:^.?!]R5@']H6:--!)CYN.
MJ_C7SK^SMXL@\*?$5(+YUBAO5,#%N`KYXS7H?77C,%-/=!8^Q?$=W+8:#J%U
M`,RPP.Z#W`K\\=6U2]UG4KF]OIY)IY'9F+G)'/3FOT:E1+F)D<!T=<%>H(->
M-:[^R[X0UG49KN"XO;)I6+/'&P*Y/ID<5Y65XREAI-5.I1\=X'H*,+Z"OK/_
M`(9#\-?]!C4?_'?\*;-^R'X;9#MUK4%/KA:]W^V\+W8'R=L'H/RI<=A^`KW/
MQO\`LNZUX>LI;W0[Q=5CC&YHV79(!_(UX;+"]O*\4BLKHVUE88VGN#7?AL72
MQ'\%B/?OA=^SKH_CWP98Z[<ZI=V\UQG<J*".#77?\,@^'_\`H.7W_?(KRWP'
M^T3K'@+PU;Z'9Z5:7$4&[#NY&>:Z/_AKSQ%_T`M/!]?,->)6I9DYOD>@'6-^
MR%X?"G&N7^?]T5R7BS]E#5=-M9;C0-434-@W&&9"C,/8^M6;/]K[5DG7[;X>
MMFB/!V2D-CVR*^AO!OBJR\;^'[76[$-Y4ZY"MU4]Q7'4Q&.PKYJKT&?GU=V=
MQI]U+:7<+PSQ$JZ,N&4CUKT;X)_"NR^)^I7]I?WD]JMK&KJ8@#G)]ZZS]J_P
MQ!IGB:PUFVA"?;8MLV.A8'_"K?['_P#R'=;.,GR$_F:]BOC93P2K0T8K'5?\
M,@>'?^@[J'Y+36_9`\/!6QKE^3VX6O5OB3XU;P%X5N=<2U%VUN5'EEMN[/O7
MAJ_MC7)X/A.+'K]J_P#L:\2A5Q]:+E3;=AAK7[(<L-N\VCZ^LLH&1%<Q8!]L
M@UX-XF\+ZEX0U.32]6M'M[J/DANCCU7VK[?^%WQ*LOB;H;ZE:P/;M$YCEA<@
M[6KRO]K;P_#)H^F:[%&JSQ2F!VZ94BNK!9C7C65&MJ*QB?#G]F[1O&'@[3M=
MN-4NHIKI!(451@&OINPM5LK&&V#,1#&J`GJ0!BOC;P=^T5XG\(Z%9Z+9V-@]
MK:J%5G4Y(^N:^Q-)NVN]-M;J10K2Q+(<=,D`G%<.:0KQFW6^00/*_&W[-VC>
M-?$=YKESJMW!-=$$J@&%_.O!_C;\*=/^%]UIL%A>7%T+I&=C)C(P:])^)O[1
M7B;P=XTU+1;&QL)(+9PJM*K$],]C7COC_P")FM?%:[T]=3M;:.>%O*B6!2"Q
M8\=37IY?#&049R?[L9E^"?`6N^/M3%CHMGYVWF23HD?U;^E>X:1^R'NB5M5U
M_:YY9+>'A3[,3S^5>Q_"OP/:^!/"5GI\,0^TM&);B0#YGD/)YKB_BM^T-;>`
M-9?1-/T[^T+V%0TI9MJ1Y[?6N>KF.)Q%;V>'`R5_9#\/`<ZYJ!;UV@5A>-_V
M8M#\+>%-3UJ#5[N62R@:55=1M.*S_P#AK[7GY_L"S4?]=&_PK+\4?M.:OXK\
M/W^B3:+:PI>Q&$NLARN?PK6G2S'G7,R=#Q0*#EB>P/IS5_0/^0YI_P#U\1_^
MA"J/.WD8SCWXQ_\`6J]H(_XGFG_]?$?_`*$*^DJ?PG<9]W4445\*:'P#0WW:
M*&^[7WCV,S]`_A7_`,D[\/?]@^'_`-!%<G\6_C;!\+=3LK&33)+XW49D!5PN
MW!YKK/A7_P`DZ\/?]@^'_P!!%?/_`.UM9W%QXHT=H()95%JX+(I..>^!7PV%
MHTZN+Y*FPS;_`.&P[;_H6Y/^_P"*NZ/^UMH][?QV^H:+<VL,A`\U'#!?J*^7
M1IM[D?Z+<?\`?HU=L/#&LZO?1V=GI]U+/,X4!8VY_,<5]#6RO!QA?]17/T%F
MBTWQ%I&)HH[RSNHP0K`,K*W3K7QI\>/AQ;_#WQ4%L5VZ=?(9H5).8R/O+^HQ
M]:^P?!NF3:-X6TK3KC`FM[6..09S\P4`_K7@?[84L(&@1-Q,?-;_`(",?UQ7
MB954E#%*$=F,]&_9OX^%>F?[S_SKS[]L7_4^'O\`??\`E7H/[.'_`"2O3/\`
M>?\`G7GW[8G^J\/?[[_RJ\-_R,?F(W_V3K"&W\#7EVO^LGNB&/T''\ZF_:KU
M&>T^'T-M&2J75TJ.1Z#G%8W[(NO13:)JNC,X\V&83(G?:>I_.NU_:$\(7/BO
MX>W$=G%YES:,+A%'\0'4#WQ4U/<Q]Y]P/B3&.AKO/@=J$VG_`!-T,Q.<2S"-
ML<<&N&E1H9"C*58'!!&"&]"#7K7[-_@N[U[QU::KY+"RTYC(TA'RLW85]+CI
MP6'DY,+'V7<HKVTJGD,A'Z5^=_BB,V'BW4XX6*>5>2!2.H.XFOT%UO48=)TB
M[O;APL4,3.Q)QT%?GAJ]P^L:W>72@R-<3O*B@'+9;@<=\5X600?--O8F9ZSX
M)_:8\3^&;6.SU*&/5K:(;5,C;)`/3/>NZB_;`T[:/.\.W()[*X-?-']GW_\`
MSXW''_3,\4?V??YYL;C_`+]FO6J97@YOF:_$H^G?^&P-(_Z%Z\_[^+6QX4_:
MC\-Z_J4.GW=A=Z>TS!$D<ADR3ZBODH:;?_\`/C<?]^S6_P"#/!.N^)-?LK6Q
MTVY8B96=S&P"`'J3@5SU\KPD8<R?XA<^_P`,CID;6##\\U\0?M`>'(O#GQ,O
MU@58X+H"X5,<`GK^M?;5G#]FM8(6&62-4)]2!7R-^TI+#J'Q8MK964B-(HY1
M]6%>/E$W"N^4;)_A1^SE+XPTZ+6->N7LK&;YHH8^)'7UYZ"O7K7]F#P!`@5[
M:[N#ZO+_`(5Z9HEE!9Z/9V\2A4CA10`,#@"OFSXT?'3Q?H/C2^T31[A+&WLR
M%#!`6<XZ\U:Q&*QE;EISL!Z@/V:/AXIS_9LP_P"VQKNO"GA+2_!FDII6D1/%
M:IR%9B>OUKXT_P"&A_B,?^8\?^_2_P"%?3?P&\5:KXQ\#Q:IJUR;BZ>5E+$8
M&`?05.883%4H7KRNO4#SO]K\?\2_0^/^6C?RK&_8_P#^0[K?_7!/YFMK]K[_
M`)!^A_\`71ZQ?V/?^0]K?_7!/YFNN'_(L8CUG]HX?\6KU+@?>3^=?$(X%?;_
M`.T;_P`DLU+_`'D_G7Q`>E=?#_\`!D3(^I/V/LG1==S_`,_*?^@BM[]J]1_P
MK>(X'%XG]:P?V/?^0-KO_7RG_H(K>_:O_P"2;Q?]?B?UKSZW_(R^970^/E!\
MQ>,<BOT;\/`?V%IW_7M'_P"@BOSD4X<'W'6OT;\.\^']./'-M'_Z"*Z.(OL$
MP/B;X_@'XJZR/^F@_E7/?#RV6Z\<Z!%)T:^AS^#`UUG[1>FS:?\`%'4I)D94
MG"2QL1PX([?2N&\*7ZZ1XFTK4';:EO=Q.Q]@PS^E>IAY*6#Y8]BC]%5`5``,
M`#BO-_$7P"\&>*-8N=4U&VN7N;IM[L)2!GZ5Z%:W*75K%<QL#'*@8>X(KYH^
M+WQD\?\`@3QM?Z;;R1168*M;%XLAE(SD'OZ5\G@Z=6=5QI.S&>BC]F'P`!C[
M)=8_Z[&N;^(?[/G@GPYX*U;5K*VN%N;6W:5"9">17E/_``T]\0_^?RT_[\BJ
M&N?M!>-_$>E7.DWUS;/;72&)U6+!P:]FG@\:I)RG^(CS;D``DCO^?.*OZ!_R
M'-/_`.OF/_T(50&2OMTQ].]7_#__`"&]/_Z^8_\`T(5]%47[IDH^[Z***^%-
MCX!H;[M%*>!7WKV,S]`?A61_PKOP]_V#X?\`T$5T5Q86=VP:XMH96'`+H#BO
MCS0?%OB:WT2RBM?$&H0Q+$@CC1AM4>GTJ_\`\)KXK_Z&74?^_@_PKX^IE53V
MC=R?:(^L/[&TW_GQM?\`OV/\*DAT^SM<M!;0Q$\DH@%?)7_":^+/^AEU+_OX
M/\*8_C+Q1(-A\2:H1Z^8!_2I_LJJ_M![1'U5K?B+2O#EE)>:E>P6L,8W%I&`
M_P#UU\4?&GXC'XC^+'NX-PT^V4Q6P/5E[L?3/]*3Q%I6JZWOEGU>\NW'\-Q(
M6'X`UPD\#VD[Q2*5D7J#7KY;ED:$O:-W8<US[8_9O`_X57IG^^_\Z\^_;$QY
M'A_O^\?^5>:^"_$_B'3M`@@LM<O[6W!.V.-@%'YUD?$C6]6U@68U/4KF]V9V
MF9@=OY5A0R^<<9[6^E[CY];%'X<>.KSX>>)[?6;3YHONSQ9QYD9ZCZU]M>#_
M`!UH?CO38[O3+N*4,N7B8_,A]"*_/O:9F"(I8YZ"NT\+:7JFCRK?6VHW5C-_
M=A8J<>AQUKJS++H5O?3LR>:Q]?:O\'?!&NWK7M]X?MGG8Y+KE<GU.*Z+3-&T
M;PII_P!FL+:WL+6,9(0!1]2>]?-]I\5O&%G`L*ZO+*<8W.`2*YKQ7XA\1^+(
MRE_KU]M/_+-6VK^(%>.LLK3]V<M!^T1U_P"T%\:;;4+23PKX?N/-1CBZN8VR
MI_V`?ZUY+\&HDF^)>@1R*KI]HY5AD?E7+ZII=UID^RX4A3]UAT-3^%[JXLM>
MM;BVGD@G1_ED3^$_XU]!2P<:.&]G3#F/T.&D:=C_`(\K;_OV*7^R=._Y\K;_
M`+]BODP^-?%F?^1EU+_OX/\`"C_A-?%G_0RZE_W\'^%?._V96_F#G1]9_P!D
MZ=_SY6O_`'[%2Q6UM;+^YBBC'^RH%?(Q\:^*\_\`(RZC_P!_!_A5>\\4^*+R
M-HY/$NJ!3W$F/Y4?V35?V@YT?3'CCXC:!X%TR:[U"]B\U5)CA#9=V],5\.>*
M/%%UXF\4W/B"X#"6>7S5!/0`_**T-?\`#VH7+/>/>W%ZYY)F<LV/;-<HRXP"
MIRIP=U>WEV6TZ*NW=BOS'W?\*OB%IOCGPO9307""[2)4GAW?,K`8S6AX@^&G
MA+Q5="ZUC1;:ZN.AD(P3]2*^*_"6F:G9,FH6^H75BS?=\ERI->@1>,/%**`O
MB34QC@'S`:\RME+C4;HR'[1(^@?^%%?#L<_\(U:_FU=3X<\-Z5X6TY+#2+-+
M2V4DB-#D`_C7RQ_PFGBP_P#,S:E_W\'^%)_PFGBP?\S+J(`_Z:#_``K">5UY
M+WIA[1'8_M?'_B7Z'_UT>L;]C[_D.ZU_UP3^9KS/XC:YJ^KQ6JZEJ=Y?*K';
MYYSCZ8JM\-]7U72+R[.G:A<63L@W&!@"1Z'->K'`R6"]C?<F^MSZM_:,P?A7
MJ0]T_G7Q"1\M>I^-/%?B+4?#\\%_K%[<0$@&*1AS]<5Y;CD9Z9KHRG"2H0<9
M/<J]SZA_8\/_`!)M=_Z^4_\`0!6_^U=@_#F+_K\3^M?/7PVUW6-*M[N/2]4N
M+%9'#$0L!GZYJ[\0?$6N:GHP@U'5;N\A,NY4F;C/X5Q5,NF\9[:XO:):'F_<
M#W_+WK[<^!_Q'L?&/A&QMGN(UU*T0130LV"=O&17Q$00,C'N*Z?PEIFH)*-1
MM[VXL3G*M"Y5C^(KOS/`QQ%-7>H^:Q]Q^)O`WASQ>J_VWI5O>%.%9QR/Q%?,
M?[2?@7P_X+OM(BT'3X[(3(Q<*20>?>FQ>,/%,2A1XEU,*!@'>,?B2*XCXC:U
MJ6K3V3:IJ5U>E58(93G%>9@<!5IU4^;1!SH]S^`GQQL+O38?#7B*[6"]MQM@
MN)#A9E^OJ*]GU3PYH'BJ%&U&QLK]"/E9U#D#KP:^`-&T2YU1]T/"J<%^PKT?
M1+S7]"B$5MXCU1%`^ZLIP/H#FKQ>41]ISTIV8>T2/J$_!OP)W\.61)]%Q7+?
M$[X6>#M)\!:W?6>A6D,\-LSQR*.5->0#QMXL(Q_PDFI`#UD'/Z5F>)/%WB6Z
MT2]AN=?OIXGC(>-V!5A^5<U++\1&:;F'.CR0G*CCGO\`G5[0/^0YI_\`U\1_
M^A"J`)"]R"![8J_H'_(<L./^7B/_`-"%?45%^Z?H%S[NHHHKX4V/@&AJ*&K[
MUF1Z5I'_`""K,X_Y9+5+7?$,FCSQQ"W1U9=V2:NZ1_R"K3_KDM<YXTADEO8&
MC1V&S^%<UPPC&4]3FC\0O_";3?\`/FGYU)!XYW.JS6@"_P"R:YC[-/\`\\)?
M^^#4D.GW5PR1I!*-W^S71[.F:<B/2H766,2#YE==P([5R7C6V2.[AN$`W2#!
M]ZZJQADMK&"%R"\:;>*Y3QM.CSV\*,-R<M6%+XM"(?$;?AC_`)`T)'O65X[Y
M%OGGFM7PQ_R!H?QK*\=?<M_K5TOXI7VBMX1TR.XNY+EURD0XXXW5U]_?1:;:
MR7$AP$'`K$\&Q[=+=NY;FCQG(ZZ:J@<2.!14]ZI8;U=C%N/%NH2RL\;HB9X&
M,XK:\/>)'U.4VUT`)!R".AKB<=>*T-#E:/5[9T_OX-:SHQ4;E3@N4[?7+!-2
MT^:,_?494^E<#8W)LKM963)1LD?I7IS*"C#'45Y??QB.]F"G_EH:6&9,#H3X
MWD_Y]1^=!\;OG_CU'YUS"QNYPJ[ZE%G<E<_9Y2/4(:KV4!V1T1\;/S_HH_.K
M=CXTCN)UCGMV3/`8'I7)-970_P"7:7_OD_X5:T[2+ZZN8U$,BKD$DKC%9NG$
MGD1Z-M!8Y.Y2,Y%<#X@LUMM9,2X"NP//UKOE0HJ+D'"A:X?QC+C6,I]Y%&:S
MH?$.&]CMH$5(41<`(!Q^%<GK?B2^LK^2"$HBIT&,YK<T348M2LH]KIYBC:03
MR:L7ND65_('F@1VQ@MTI))2]Y$1]V6IQ0\6:J!_K$_[YKK/#EY+J&FK<3OOD
M)P>,4?\`",:6?^78?F:O6=E%80""%`B`YIU91:LAS:.;\<_ZNV^IJ+P4/](N
M!VVBIO'7^JMOJ:A\%_\`'U<?[@JO^794?A-CQ0!_8\_'<5P/0@>XKO\`Q3_R
M!I_J*\_'WAQW%7A2X'7>"!^XN1_MBK/C,?\`$L7I]^JW@C_4W7^^*M>,_P#D
M%C_?J)?Q#/[1PY`)YQ@\5Z?IT0@M($7H(P,?A7F!'TKU"T'[F+_<7^0JL5L.
M9SGB3Q'<V5V;2U(4K]YL5SUWJ=WJTD8G8,00GIUJ;Q$?^)Q<56TI%DU&W5ON
MF05I3@E"XTO=/0M,L8["QB@C7H`6(ZY-8FO>)YK&\-K:QJ6C^\YKIPH#$#@"
MJ4^C:=/.TKVL;ENI(-<L9+FU,EN<B?%VJ==T?_?-1W'B?4;J"2%VCVN,'"UV
M'_"/Z7_SY0_E5/5M#T^'3IY([6-75>&%:QJ1[&B:.$/`&1DXVFKV@#_B=Z?_
M`-?$?_H0K/!;:I(P#6AH'_(<T_\`Z^(__0A6U7^&S8^[J***^%-#X!H;I10U
M?>F9Z5I/_(*M?^N:U<95/50?PJGH_P#R"[;_`*YK6#XPN[BUN85CD>/<O\+5
MPI7F<]KR.JV)_<'Y4H50?E4#'>O,O[4OO^?N7\ZEM-<U&UD1DN7)]":U]@RN
M0]!U)KE+1GM8T:8=`37F]U+--<R-<9\S=\VX=*])M9#<6L<[(5,B[L>E<AXS
MLT@OHYD7Y9E^;\*F@[.PH;V-[PQ_R!H?QK*\=?=M_K6IX7.=&AS@=>]97CG!
M%OC!YIP_B#^T2^";M%2:V;_6'YP*U_$.FMJ6GR1QC$B_,M<!I]W)8727$389
M3\P/I7?Z9K=IJ<:E)`DO\2,>?P]:*D&G=!.&MSSN6&2)V1U=67U%;WA/1YI[
MP73QE(H^A;^*NR>TMYFW/#&Y]2*=+)!:IEW2)%[$XHE6<ERB]H-NIA;VLLI.
M`J]^]><V=K)JVH>2G61RQ8=JU/$?B(7G^C6S?N@>?]JG>"8U;4))#_"E.*<(
MW925E<Z>PT:RTZ-%C@4G^)FZFKQ55&,`#VIEU)Y$$DH&652:\XNM7OKJ=I&G
MD`)XPV-M9PBY]2(JYZ3M7VI>$Y4[3ZUYA]ON_P#GYE_[ZH:\N7_Y;R_]]5?U
M7S*Y#T.^U:TTZW:225"W9!][\J\[O[U[^]DG<%6D.5/M43.TARS$GU-%;4Z:
M@..@Z*22%MT3,I'/RG%6QKNI(H`NIE_6NL\,VT,ND1-+!&S9/)&:U?L=H?\`
MEA#^"U$ZJ3M8)S.!&O:M(<1W,S$]L5V^B"Z%A&]V6>5AGY^,5:6UM8Q^[AB%
M0WFHVME'F>9%`'`W<UC.2FK)$MW.=\<'!MD[L":9X*_X^KG_`'16/K&JMJMZ
MT^,1K\J*>"/>MCP3Q<7/0':*V:M3U';2QL^)P3H\P`R<CBN!$4O]QQ_P&O5&
M".,,%-,\B'^XE8PK<O0(RL8'@VSDM[*228%=YRJD8-.\:.BZ9&.[/6S/<VUJ
MN995C4=R:XKQ1K":C<I'$?W,8('U]:=-.4KB6LC$P?3O7J=F/W,/^X/Y"LC0
M+&U?2(&DAA<D=2.:V55=JJ`5"]`!1B'?0)STL>>^(P1K,_%4;63R+J*4](V#
M?D:]+>RLY&+26\3-ZD5ROC*W@MW@$2(H8=`*VI5.9<HX3OH=9%*LD:21\[P&
M_.N2\0W>JV-_*4GF6%C\I'0U)X=\2)!"+.]^ZOW9/Z5U"M:W:95XY5(R.<UB
MTZ;N+9W//_[=U0?\O4GY_P#UJ9+K6HR(R27,C*PY!_\`U5Z%]DM?^><7Y52U
MFVMTTRX*11@[>P]ZN-5=AIGG>6P`QS@UHZ!_R'-/_P"OB/\`]"%9X'`XK0T#
M_D.:?_U\1_\`H0K:K\+-C[NHHHKX4T/@&AJ*4]*^],STG1_^039_]<EK.\1:
M!<:M/%)"ZC:O\5&F>(M,@L+>*6Y5&5-K<&K?_"2Z5_S]K_WR:XGSQ=TCF][F
M.=_X0F^_OQ?E3X/!5QYL9FG0*/[HKH/^$ETG_G[7_ODU$WBC2!TNMW_`35>T
MJ=A\\C6CB6.-857"HN.:X[QQ<QR74,$?WHURU:%[XSMHXV2U1I7]6KC+BXFN
M)VFD;=*S;MU70IN]Y%0AK<W=,\.WNH6B3PW@B20XQS577-)NM-$/GW`EW'''
M-;N@:UIUGID4,\P60'=C%4/%NHV>H"W^RRAC&<\"G>7/L/4YS'>E!*-N4E6'
M3VI.U%;FA:75;Y5VK=3*H]&S4<MW<7!W3.[MZ,U0[:"*+"Y0[5N^#[M(=4VO
M\OF#`K"I\<C1.KJ<,IR*F:NK$GJDB+(A5AP1BN1O/!,C2[[6<!22VUA4NG>-
M(658KZ-P>@=16HOB?2F7)NL?[RUQVJ0V(Y'$Y_\`X0F^_OQ?E1_PA-]_SUB_
M*NC/B32O^?M?^^31_P`)+I/_`#]K_P!\FM/:5.PN>9S9\$7^/]?%Q[5A.C0L
MR,064E3BN_;Q)I1!'VM>GH:X&Z*M<2E6#)O)!'O6U-R>YK"_VAJW4\8VJ[*/
M8TOVRY_Y[O\`G4>VC;6EBQ_VJX_Y[2?G2,[/]]BWUIM%`!CO3UD>,YC=E/L<
M4RB@1+]KN?\`GX?\Z3[7<?\`/P_YU'1BBPN4<TDD@^9V;ZFDVY/2DHJD42I=
M3J-H=P,]C7J%N,P1DG)*+_(5Y7QD9/0YKO[;Q-I0CB22Y52H`/RGT%<V(BV]
M#&9ROB"ZFCU>=5D8#M@UEM/++_K'+8]35[7;F&\U2::$@H_((%9U:TOA+C\(
M[MSTIRRR1\H[+]#BF4511+]KN?\`GX?\Z:US.Z[7E9A]:9MHQ0+E%[5?T#_D
M.:?_`-?$?_H0K/K0T#_D.:?_`-?$?_H0J*OPLH^[J***^%-#X!H:BAONU]Z]
MC,^A_!O[+^G>)_"^GZW-KMS`UY`LI0(/ES6I_P`,E:)_T-DWY+7IW@B.2?X+
M:?'`K-+)I05%7J3LKY*/PZ^(ID8#0M>SD_P/ZU\M0Q-:K4FG6Y;#/1_&'[+.
MHZ'I-SJ6BZLFI^6I<P-'AB/4'/6J/P\_9\L_&G@<^))=8GMI"KGRD0=5[5[Y
M\)].U;1_AA9VWB+S!=QQ2&196^9%YP#^%4?@@MO=_#>8(56TDN;H*5[*7./T
MKGEF==*2YKV=KV%RGQ*R[2?8FDKZ0TCPW\!)-4BT'SI[Z_DD\H2N\@#2=.V!
MUKF/CY\'M+^',=CJ>BNXL[N3RFAE;)C<`D$'KV->]1S2#DJ<TTWM<#Q;WHP!
M7TAX5^$_PTT?P9'K?BJ\&H7+0":6..?E,C(4*ISFKGA+P5\%?B1-/INC:;?V
MMY&A<"220,!ZC)(-1/.:49.R;2W?0#YD[4E>OQ?"6PT/XV6G@[4"]WI\V'`)
M*ET(/4CW%>D^,OAA\&_`=S:3ZXMQ;Q3@I';K([;V_O<'/%5/-Z2:BDW?:P'R
MO17T?\4/@AX3T[PS:^)/#:26\+21EHS(S++&Q'KR.M='XD^!WPOT/P[;ZSJ0
MGTV!/+>:596;=D?=P<]:AYS1LGRO5V`^3=M+7U-X5^&_P7^(T-W:^&XK@W$"
M_,^^0,F>_P`W%8=Y\/\`X-?#N^.D^+=1NK_4"=V,N/+4]!\M5_;%._+RN_:P
M'SIUHKZ.^*OP/\)6'@67Q7X46:W2&,3!"[,DJ?0\UG_"OX2^`[_PB/$?BN_6
M>5E,AMEN-NQ1[#G-"S:C[-U+/TZ@>`T;:^E?#WAWX$>,-831=,TV^BO)<B(R
M-*H8^Q)KB/B1\$O^$8\=Z7H6DS.UIJK@0-)R\1[CW`JJ6:TI2Y9)J_<#R&CB
MOJ/6/A'\)/AEIELWBY[BXN)_E5F=_G8=<!/ZTZP^#OPG^(V@7%WX1>>UDCRB
MR>:_RN/4.?Y5#S>DU?D=N_09\M45['\)/@E%XQ\0:I;ZU.ZV.E3F!UC&#(X/
M0'TKLK_1OV?M(U"72KJWNS<POY;MF8A6Z=1Q3JYM24E"*;]!'S52U[U\9/@;
MH?AGPN/%?A>646@VEX9&W`JW0J>M;5_\%_!]O\''\316#C5/L(G$HF;&X@=L
MXJEFU%J,EU=AGS90H9F`3.XG`QWKN?@MX5TSQCX^LM)UB)IK2:-V9%?!X''3
MFO2/'GP^^'G@+XE:+:7=M+:Z+/"7F`D=B9,_+WS^57B,RIPFZ23N(\<U'P'X
MFTG3FU2^T2]M[/`/G,ORX/2L.WA6>XBB<[5D=4SZ9/6ON_QZO@\^`@OB,R#0
M"L>"I;./X>G-?-GQ!@^#TFD0+X+>9M1-Q&I4F093//WN*Y<)FKJQ:E%_+]1\
MH?$#X,Z'X0\%KKEGXC6\N/W?^C@K_$.>E>/GI7TI\6?A!X8\.?#:+5=*LIH[
MYW@4.\[N/FZC!..M3:7\#/`/@[P=#K_CF>:9G56DPY549A]T!:C#9G&$+R;;
M;ML!\R]:-M?4GACP!\#_`(BK<6GAZ.>.YB7+-YLBE??YC@UY+<?"J"S^*_\`
MPAEYJ:1V8D#M=,P7]V1D=>-U=E+-*4N9--/S%8\VQB@<'./>OIKQ'X-^"'@1
M;:VU.TNM1FE4_O(978G'=MI`%27?P0^'WC?P5-K_`(,%U9NJ2-$69F#,O52&
MSW%8K.*3?O1:7>P'`_!SX'V?Q/\`#]YJ-QJ<]J;><Q"-5_V0>OXUY;X@TM-&
MUN]TY)&D6VF:(.PQG:<5]2?LFQM'X,UI&&TIJ#*PQC!"`$5Q7PY^$>F?$7QY
MXGO-:DE^RV5ZRB%#@LQ)/-<U',G"M5E.7NH+'@7I17T?KFG?`?P_K,NBWFC:
MDUQ;R>5(X,NU6'&<YKF_C!\./`&CZ`-8\(:S;^:C+OL_M(D9E;N!G(KLHYM"
M<U%Q:OUMH!XG6AH'_(<T_P#Z^(__`$(50J_H'_(<T_\`Z^(__0A7HU?A8'W=
M1117PIH?`-#?=HHQGBOO69GW;\/;M]-^#^DWJ`.\&FK*H/LE>$G]KSQ6'(&C
MZ5U(Z-_C7%67QU\::9H*>'8KVW2TBA^SB,P@G9CU^E>?$$G=WSDUX.$RB/M*
MDJZO?8.8]5\5_M'>-/$^GRZ:7LK""<,LAMD.XK]23^E>Z_`#CX*KS_#<?R-?
M&G6N]\._&?QAX1\/?V+IMS;QV(W*%:($\]:TQF5\U%4Z*2UN!A^`\GQSHW7_
M`(_D_P#0A7TI^UC"D_ACP]%(<))J*JQ]`4-?*NFZA=:7J-O?VDFV>"02(2/X
MNU=5XT^*_BCQYIUO9Z]=QS06TOFIMC"G.".WM3Q6!G4JTYQV6X7/JC5+:#X:
M?#Z&\\*>&(M7N%BC7R88\M*#C+'`)/K69\*?&6M^*_$$K:OX"_L1XXB4O#`8
M^_*Y(KY^\/?'SQUX7TV&SM=32>VB7:BW,08JOH".?SJTW[2?Q$FNXY%U*W0X
M^6)8!M;ZUYTLHKZQLG?K<.8]2\5_\G2Z-_U[1_\`LU87[8`QK/A_''[I_P"8
MKRJ\^*?B:_\`%T7BVYN(VU.U01+(L8"CKCY>_6JGCGXBZ]X^GM9?$$\4TEN"
ML16,+@'Z5U87+:M.M";M9;AS$=GXLU^]GL].N]:OYK+S440M,2F`>!C.*^G?
MVCQ_Q9F/G^*#^E?(4,K6\\<\9P\9##ZBNU\3_&'Q9XST'^P]3NK>:S!4D+"%
M/R].:[,7E\IUJ<Z=K)W8KGIG['O_`"'=<_Z]T_\`0JXC]HD_\79U/O\`+'_*
MN:\$?$+7?`$US<>'[A(I+E`KEHPW0^]9OB?Q-J7BK6IM5U257O)2`[*@7/Y5
M,,)4^MRK=&K#YCZV\3D#]G9LG@Z:G\J/A_H&F^$/A/:ZOHFBIJ>H-:"9D5<R
M3N>V?Z5\WWOQJ\67/A@^&9[N#^SS"(#&(1NV_6CPA\9O&/@JQ33M+U,M;#YD
MBF0.!]">17G/*Z[A))];^H7/??`OCWQ'XK\6V=OK'PX.GPY)6\:W93;D#KDK
MC\J=\7[^*R^+'@>:9@D8E9<GU/%>,3?M)_$.XD1TU*"%5[)`O/YURGC3XE^(
M_'5Y:3ZY=H\MF287C380?PJZ645_:*4DDO4.8^@_VHO!^N^)X=&N=%TVXOD@
M+B18$WLN>^*X[X7?L_ZYK&C7-YJ^HZEX=97)2+;M)'J0>E<EHG[1/C_1(19I
MJ<=TJ(%1;B(,0/J,'\\TS7/VAO'^LV4EI+J45M%(I5O(B`)_&M*>#QE.#H1:
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M=SZM^+&DWWB#X,I:Z7:RWEP\,#+%$,LP`["O';WX`1>'?`UOXIU'4YX+Y?+=
MK-XL!7+#Y>><UR^@?'[QSX5T^+3K74(Y8(0%07,>\J/KZ5G>+_BYXP\9PHFK
MZB#;1R!EAAC"IN'()[G\:PHX#&4FX0:LW<.8^E_CA,D'PGT^60@(D]HSGT`/
M--^.&AZAXM^$MO#H5M)>S;X)A'#R64#J!WZU\V>)?C)XK\6Z`=!U6YMY;'Y2
M56$`_+P.:L>%?C;XZ\)6*V&GZF9;6%<B&=%<(/8GFLX91B(I3C:Z=PYC?^%G
MP-\2Z_J-R-275?#L4:#;+Y1C,A]/>MWP/\.=)M_CO+X?U._;6X[*V,VZXYWR
M<<$9.<9_2N6O?VE?B'?Q-$M_;6P88S'$,_G7`VGB?6+#7AK=M?W":F'+^>6R
MV>_/<>U=7U/&57+VC2]`N?6?Q-\<:[X-U*+2]"\`?VI:%`3,L!=,^F`*ZCP1
M>W&I>`7O+KP__8$\R3,]GLV[3S\V,=^M?,]M^TQ\0A$(A>6LC8QO,`R*JC]I
M#XA?9Y89-4BE1]P;=`O&>PKB>3XBRC97[W"Y[1^RISX4\0_]A-__`$$5S?P>
MA\3KXZ\7W'AZXTUH1?,MQ;W>X'[QPRX_&O)O!/Q@\4>`;"XM=(DMD@N9S-(9
M8@27(YZ>U9FB?$#Q)X=\17>M:5?O;7MRY:?8!L?//*GBMUE==\^WO!S'T?KO
MQ5\2Z;K%SI]U\+)]2,3[!<1(S+*/[P.P_P`^].^-'@WP_J_PPGU^?18-)U)(
MHYE8(%>,DC*-C&>N*\C'[4'Q"11NN+#ZO!S^E<KXS^*GB_QU:"#6M3>2T!W>
M3&H1"?<#K^-*CE6(52,K)6ZW8<QQF3M!`.6Y/I6AH'_(<T__`*^(_P#T(50Q
=Q5_0?^0YI_\`U\1_^A"OH:OP,#[NHHHKX4T/_]D_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
